

Interventions for the prevention of OHSS in ART cycles

The Cochrane Library

2017, CD012103

DOI: [10.1002/14651858.cd012103.pub2](https://doi.org/10.1002/14651858.cd012103.pub2)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Assisted reproductive technology in Japan: a summary report of 1992â€“2014 by the Ethics Committee, Japan Society of Obstetrics and Gynecology. <i>Reproductive Medicine and Biology</i> , 2017, 16, 126-132.	1.0	70
3	Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing IVF/ICSI. <i>The Cochrane Library</i> , 0, , .	1.5	3
4	Clinical parameters of ovarian hyperstimulation syndrome following different hormonal triggers of oocyte maturation in <scp>IVF</scp> treatment. <i>Clinical Endocrinology</i> , 2018, 88, 920-927.	1.2	36
5	Hyper response to ovarian stimulation affects the follicular fluid metabolomic profile of women undergoing IVF similarly to polycystic ovary syndrome. <i>Metabolomics</i> , 2018, 14, 51.	1.4	17
6	Follicular aspiration versus coasting for ovarian hyper-stimulation syndrome prevention. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2018, 39, 290-295.	0.5	1
7	New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 663-671.	0.8	44
8	Progestin-primed milder stimulation with clomiphene citrate yields fewer oocytes and suboptimal pregnancy outcomes compared with the standard progestin-primed ovarian stimulation in infertile women with polycystic ovarian syndrome. <i>Reproductive Biology and Endocrinology</i> , 2018, 16, 53.	1.4	13
9	Genome-wide screening differential long non-coding RNAs expression profiles discloses its roles involved in OHSS development. <i>Journal of Assisted Reproduction and Genetics</i> , 2018, 35, 1473-1482.	1.2	5
11	Stem Cells as a Resource for Treatment of Infertility-related Diseases. <i>Current Molecular Medicine</i> , 2019, 19, 539-546.	0.6	32
12	Personalized prediction of live birth prior to the first in vitro fertilization treatment: a machine learning method. <i>Journal of Translational Medicine</i> , 2019, 17, 317.	1.8	40
13	Assisted reproductive technology in Japan: A summary report for 2016 by the Ethics Committee of the Japan Society of Obstetrics and Gynecology. <i>Reproductive Medicine and Biology</i> , 2019, 18, 7-16.	1.0	27
14	Flexible GnRH Antagonist Protocol versus Progestin-primed Ovarian Stimulation (PPOS) Protocol in Patients with Polycystic Ovary Syndrome: Comparison of Clinical Outcomes and Ovarian Response. <i>Current Medical Science</i> , 2019, 39, 431-436.	0.7	28
15	Clinical pregnancy following GnRH agonist administration in the luteal phase of fresh or frozen assisted reproductive technology (ART) cycles: Systematic review and meta-analysis. <i>European Journal of Obstetrics and Gynecology and Reproductive Biology: X</i> , 2019, 3, 100046.	0.6	6
16	In-vitro fertilization resulting in heterotopic pregnancy, ovarian hyperstimulation and paralytic ileus: A case report. <i>Case Reports in Women's Health</i> , 2019, 22, e00106.	0.2	0
17	LH Levels May Be Used as an Indicator for the Time of Antagonist Administration in GnRH Antagonist Protocolsâ€”A Proof-Of-Concept Study. <i>Frontiers in Endocrinology</i> , 2019, 10, 67.	1.5	21
18	The Role of GnRH Agonist Triggering in GnRH Antagonist-Based Ovarian Stimulation Protocols. , 2019, , 363-377.		0
19	Rare genetic variants suggest dysregulation of signaling pathways in low- and high-risk patients developing severe ovarian hyperstimulation syndrome. <i>Journal of Assisted Reproduction and Genetics</i> , 2020, 37, 2883-2892.	1.2	4
20	Association of Metformin With Pregnancy Outcomes in Women With Polycystic Ovarian Syndrome Undergoing In Vitro Fertilization. <i>JAMA Network Open</i> , 2020, 3, e2011995.	2.8	41

#	ARTICLE	IF	CITATIONS
21	Late-onset ovarian hyperstimulation syndrome developing during ovarian stimulation in an ectopic pregnancy: a case report. <i>Journal of Medical Case Reports</i> , 2020, 14, 110.	0.4	2
22	Cumulative Live Birth Rates After the First ART Cycle Using Flexible GnRH Antagonist Protocol vs. Standard Long GnRH Agonist Protocol: A Retrospective Cohort Study in Women of Different Ages and Various Ovarian Reserve. <i>Frontiers in Endocrinology</i> , 2020, 11, 287.	1.5	11
23	The perspective of women with an increased risk of OHSS regarding the safety and burden of IVF: a discrete choice experiment. <i>Human Reproduction Open</i> , 2020, 2020, hoz034.	2.3	19
24	Clinical Germline Genome Editing: When Will Good be Good Enough?. <i>Perspectives in Biology and Medicine</i> , 2020, 63, 101-110.	0.3	2
25	<p>Progesterin-Primed Ovarian Stimulation with Dydrogesterone versus Medroxyprogesterone Acetate in Women with Polycystic Ovarian Syndrome for in vitro Fertilization: A Retrospective Cohort Study</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 4461-4470.	2.0	26
26	Acute cardiovascular changes in women undergoing in vitro fertilisation (IVF), a systematic review and meta-analysis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 248, 245-251.	0.5	16
27	Live birth after in vitro maturation versus standard in vitro fertilisation for women with polycystic ovary syndrome: protocol for a non-inferiority randomised clinical trial. <i>BMJ Open</i> , 2020, 10, e035334.	0.8	6
28	Infertility management in women with polycystic ovary syndrome: a review. <i>Porto Biomedical Journal</i> , 2021, 6, e116.	0.4	25
29	Fresh versus frozen embryo transfers in assisted reproduction. <i>The Cochrane Library</i> , 2021, 2021, CD011184.	1.5	48
30	Exosomal miRâ€27 negatively regulates ROS production and promotes granulosa cells apoptosis by targeting SPRY2 in OHSS. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 3976-3990.	1.6	6
31	Monitoring of stimulated cycles in assisted reproduction (IVF and ICSI). <i>The Cochrane Library</i> , 2021, 2021, CD005289.	1.5	6
33	Effects of controlled ovarian stimulation on vascular barrier and endothelial glycocalyx: a pilot study. <i>Journal of Assisted Reproduction and Genetics</i> , 2021, 38, 2273-2282.	1.2	3
34	Nomogram Model to Predict the Probability of Ovarian Hyperstimulation Syndrome in the Treatment of Patients With Polycystic Ovary Syndrome. <i>Frontiers in Endocrinology</i> , 2021, 12, 619059.	1.5	4
35	Successful outcome of a pregnancy derived from premature ovulation in a gonadotropinâ€releasing hormone antagonist protocol: A case report. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 883-886.	0.2	1
36	Lipidomic Components Alterations of Human Follicular Fluid Reveal the Relevance of Improving Clinical Outcomes in Women Using Progesterin-Primed Ovarian Stimulation Compared to Short-Term Protocol. <i>Medical Science Monitor</i> , 2018, 24, 3357-3365.	0.5	19
37	Effect of kisspeptin-54 on ovarian levels of pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in an experimental model of ovarian hyperstimulation syndrome (OHSS). <i>Reproduction, Fertility and Development</i> , 2021, 33, 799-809.	0.1	3
38	Clinical Pregnancy and Incidence of Ovarian Hyperstimulation Syndrome in High Ovarian Responders Receiving Different Doses of hCG Supplementation in a GnRH-Agonist Trigger Protocol. <i>Evidence-based Complementary and Alternative Medicine</i> , 2021, 2021, 1-7.	0.5	4
39	HCG Trigger After Failed GnRH Agonist Trigger Resulted in Two Consecutive Live Births: A Case Report. <i>Frontiers in Reproductive Health</i> , 2021, 3, .	0.6	1

#	ARTICLE	IF	CITATIONS
40	IVM in patients with high risk of OHSS. Russian Journal of Human Reproduction, 2020, 26, 47.	0.1	0
42	Gonadotropin levels at the start of ovarian stimulation predict normal fertilization after hCG re-trigger in GnRH antagonist cycles. Reproductive Medicine and Biology, 2021, 20, 96-107.	1.0	1
44	Efficacy of fresh embryo transfers in cycles with GnRH agonist triggering. Russian Journal of Human Reproduction, 2020, 26, 65.	0.1	0
45	In vitro maturation without gonadotropins versus in vitro fertilization with hyperstimulation in women with polycystic ovary syndrome: a non-inferiority randomized controlled trial. Human Reproduction, 2022, 37, 242-253.	0.4	18
46	ANG II, VEGF in Ovarian Hyperstimulation Syndrome. Acta Endocrinologica, 2020, 16, 30-36.	0.1	3
47	Comparison of Dydrogesterone and GnRH Antagonists for Prevention of Premature LH Surge in IVF/ICSI Cycles: A Randomized Controlled Trial. Journal of Family & Reproductive Health, 0, , .	0.4	2
49	Comparison of Dydrogesterone and GnRH Antagonists for Prevention of Premature LH Surge in IVF/ICSI Cycles: A Randomized Controlled Trial. Journal of Family & Reproductive Health, 2020, 14, 14-20.	0.4	2
50	Semi-automated versus manual embryo vitrification: inter-operator variability, time-saving, and clinical outcomes. Journal of Assisted Reproduction and Genetics, 2021, 38, 3213.	1.2	6
51	Pregnancy outcomes in patients with late-onset severe OHSS following different methods of ascetic fluid drainage and a comparison with non-OHSS IVF patients. Archives of Gynecology and Obstetrics, 2022, , 1.	0.8	1
52	Fertility preservation in transgender men without discontinuation of testosterone. F&S Reports, 2022, 3, 153-156.	0.4	8
53	The novel oral gonadotropin-releasing hormone receptor antagonist relugolix is a new option for controlled ovarian stimulation cycles. Reproductive Medicine and Biology, 2022, 21, e12448.	1.0	0
54	Effect of GnRH agonist alone or combined with different low-dose hCG on cumulative live birth rate for high responders in GnRH antagonist cycles: a retrospective study. BMC Pregnancy and Childbirth, 2022, 22, 172.	0.9	3
55	Oocyte quality in assisted reproduction techniques. Minerva Endocrinology, 2022, 47, 89-98.	0.6	4
58	Dual Trigger Compared with Human Chorionic Gonadotropin Alone and Effects on Clinical Outcome of Intracytoplasmic Sperm Injection.. International Journal of Fertility & Sterility, 2021, 15, 294-299.	0.2	0
59	Algorithm-based individualization methodology of the starting gonadotropin dose in IVF/ICSI and the freeze-all strategy prevent OHSS equally in normal responders: a systematic review and network meta-analysis of the evidence. Journal of Assisted Reproduction and Genetics, 2022, 39, 1583-1601.	1.2	6
60	Comparison of bromocriptine and hydroxyethyl starch in the prevention of ovarian hyperstimulation syndrome. International Journal of Gynecology and Obstetrics, 2022, 159, 944-950.	1.0	4
61	Association of Polycystic Ovary Syndrome Phenotypes With Adverse Pregnancy Outcomes After In-Vitro Fertilization/Intracytoplasmic Sperm Injection. Frontiers in Endocrinology, 2022, 13, .	1.5	5
62	Comparison of 3 Different AMH Assays With AMH Levels and Follicle Count in Women With Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3714-e3722.	1.8	7

#	ARTICLE	IF	CITATIONS
63	The effect of higher estradiol levels during stimulation on pregnancy complications and placental histology. <i>Placenta</i> , 2022, 126, 114-118.	0.7	4
64	Kallistatin prevents ovarian hyperstimulation syndrome by regulating vascular leakage. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 4613-4623.	1.6	2
65	Gonadotropin releasing hormone (GnRH) antagonist administration to decrease the risk of ovarian hyperstimulation syndrome in GNRH agonist cycles triggered with human chorionic gonadotropin. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 1731-1737.	0.8	0
66	Use of gonadotropin-releasing hormone (GnRH) agonist trigger in fertility preservation for patients with inherited genetic disorders. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	2
67	Increased risk of abortion after frozen-thawed embryo transfer in women with polycystic ovary syndrome phenotypes A and D. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
68	Ovarian hyperstimulation syndrome in assisted reproductive technology programs in the Republic of Bashkortostan. <i>Kazan Medical Journal</i> , 2022, 103, 761-772.	0.1	0
69	Is a freeze-all strategy necessary for all embryo transfers? Fresh embryo transfer without progesterone elevation results in an equivalent pregnancy rate to cryopreserved embryo transfer. <i>Journal of Medical Investigation</i> , 2022, 69, 224-229.	0.2	1
70	Mesenchymal stem cells to treat female infertility; future perspective and challenges: A review. <i>International Journal of Reproductive BioMedicine</i> , 0, , .	0.5	2
71	Analysis of relative factors and prediction model for optimal ovarian response with gonadotropin-releasing hormone antagonist protocol. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	1
72	The effect of frozen embryo transfer regimen on the association between serum progesterone and live birth: a multicentre prospective cohort study (ProFET). <i>Human Reproduction Open</i> , 2022, 2022, .	2.3	9
73	Anesthesia for Assisted Reproduction. <i>Recent Advances in Anesthesiology</i> , 2022, , 305-321.	0.0	0
74	Perinatal outcomes of singleton live births after late moderate-to-severe ovarian hyperstimulation syndrome: A propensity score-matched study. <i>Frontiers in Endocrinology</i> , 0, 13, .	1.5	0
75	Frozen embryo transfer in the menstrual cycle after moderate-severe ovarian hyperstimulation syndrome: a retrospective analysis. <i>BMC Pregnancy and Childbirth</i> , 2022, 22, .	0.9	1
76	Low LH level does not indicate poor IVF cycle outcomes with GnRh-a single trigger: a retrospective analysis. <i>BMC Pregnancy and Childbirth</i> , 2022, 22, .	0.9	2
77	Intrafollicular fluid metabolic abnormalities in relation to ovarian hyperstimulation syndrome: Follicular fluid metabolomics via gas chromatography-mass spectrometry. <i>Clinica Chimica Acta</i> , 2023, 538, 189-202.	0.5	2
78	The investigation of cholinergic receptor muscarinic 1 activity in the rat ovary with induced ovarian hyperstimulation. <i>Tâşrk Jinekoloji Ve Obstetrik Dernei Dergisi</i> , 2023, 20, 53-58.	0.3	2
79	Managing ovarian hyperstimulation syndrome: A qualitative interview study with women and healthcare professionals. <i>Journal of Clinical Nursing</i> , 2023, 32, 6599-6610.	1.4	0
81	Introductory Chapter: IVF Technology and Perspectives. , 0, , .		0

#	ARTICLE	IF	CITATIONS
82	Risiken und Komplikationen der Kinderwunschbehandlung. , 2023, , 405-420.		0